Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Takeda And Biological E. Limited Enter Strategic Partnership To Accelerate Access To Dengue Vaccine In Endemic Areas

Author: Benzinga Newsdesk | February 27, 2024 03:30am
  • Biological E. Limited (BE) to Manufacture Up to 50 Million Doses of QDENGA Per Year, Accelerating Takeda's Ability to Deliver 100 Million Doses Per Year by 2030 At the Latest
  • Addresses the Specific Need to Offer Multi-Dose Vials for National Immunization Programs to Help Protect the Most Vulnerable Populations
  • Dengue Incidence Continues to Increase and Poses a Growing Threat to Public Health Worldwide

Posted In: TAK


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist